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Introduction 
When the immune system of a vertebrate encounters a new 
antigenic threat, it responds by entering two mutually exclusive 
pathways to produce separate populations of dispatching cells, 
known as armed effector cells (Wong, 1996) and memory cells 
(Zinkemagel, 1996). The larger pool of short-lived armed 
effector cells are responsible for directly clearing the immediate 
pathogenic threat. The distinct population oflong-lived memory 
cells insure that subsequent threats from the same pathogen will 
be recognized and cleared with greater expediency (Zinkemagel, 
1996). A pharmacological method to intentionally modulate this 
differentiation pathway to generate more memory cells would be 
ideal within the scheme of vaccination. 
Abstract 
Immunological memory, acquired either by previous 
infection or vaccination, affords vertebrates a large margin of 
survival. Subsequent exposure to a "remembered" pathogen 
signals memory cells to undergo a rapid, clonal proliferation 
into armed effector cells. This rapidly mobilized clone mediates 
the specific clearance of the trespassing pathogen. Typically, 
this secondary recall response effectively dispatches the particular 
pathogen prior to any manifest disease pathology. This is the 
age-old, enjoyed benefit of immunity. Though this appreciation 
for immunological memory has been in documentation for 
nearly 3 millennia, our ability to intentionally increase its 
normal/eve/ of formation is only now beginning. The Durdik lab 
and collaborators previously demonstrated that the presence of 
pentoxify/line (PF), a clinically administered phosphodiesterase 
inhibitor, during priming, produces a decrease in the primary 
response and a substantially increased memory response within 
the CD4 helper T-ee// contingent. Here it is shown that the 
presenceofPF during priming results in enhanced CDS cytotoxic 
secondary responses. CDS T-cel/s respond by directly killing 
cells hosting intracellular infections. A significantly enhanced 
cytotoxic memory response was demonstrated both 60 and 90 
days post-priming to a specific peptide antigen called HY (amino 
acid sequence: KCSRNRQ YL) under a P F-cover during priming, 
in contrast to groups without P F administration. These findings 
suggest a substantial potentia/for the development of enhanced 
vaccines for intracellular pathogens. 
The Durdik lab and collaborators previously demonstrated 
that the presence of the phosphodiesterase inhibitor, pentoxifylline 
(PF), during priming modulates the differentiation pathway of 
CD4 helper T -cells to favor a larger commitment of memory 
cells at the expense of armed effector cell proliferation (Gupta, 
1999). The hypothesis followed that the presence of PF during 
priming would shift the immune cell differentiation pathway 
such that the immunological memory CDS killer T -cell response 
wouldbesignificantlyenhancedascomparedtonormal,untreated 
levels. The following experimental design provided conclusive 
data that a CDS T -cell memory response, both 60 and 90 days 
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post-priming, can be enhanced with the presence of PF during 
priming. 
Experimental design-Materials and methods 
Pentoxifylline 
Pentoxifylline (PF), a phosphodiesterase inhibitor, is a 
clinical agent commonly administered as an anti-inflammatory 
and blood thinner (McEvoy, 199S). It has been demonstrated 
that the phosphodiesterase inhibitory function of PF increases 
intracellular levels of the ubiquitous, secondary messenger, 
cyclic adenosine monophosphate (cAMP) (McEvoy, 199S). 
Antigenic system 
Memory CDS T-cells were generated within an in vivo 
mouse, HY -antigen system. The genetic variance between 
genders of the syngeneic inbred C57BUJ6 mouse strain (Jackson 
Laboratory, 19S9), namely, the male possession of the HY-
antigen encoding Y-chromosome (Scott, 1995), provided the 
immunogenic basis for the system. Each experimental time-
point, day 60 and day 90, consistedof2-3 eight-week-old female 
C57BUJ6micethatreceived,ondayO,apriminginjectionofl07 
male C57/BUJ6 splenocytes. In some experiments, 107 
B6. THY 1.1 male splenocytes were employed as primers. These 
splenocytes possess two immunogenic differences (HY and 
THYl.l) relative to the female C57BUJ6 mice. This was 
performed to increase the overall helper CD4 immune response 
and subsequent recall cytotoxic CDS activity. Half of the mice 
received PF injections (1.5 mg/mouse) once a day from day -1 to 
day4. FemaleC57BUJ6micethatdidnotreceivePForpriming 
injections were employed as controls. 
In vitro effector:stimulator cultures 
At the experimental time-points, day 60 and day 90, 
splenocytes from each group were harvested and cultured with 
male C57BUJ6 stimulator-splenocytes ina single cell suspension 
at a ratio of 5: 1 ( 107 effectors:2X1 ()6 stimulators). These cultures 
were incubated at 37oo C in 5% CO, for 6 days to allow the 
priming-generated. HY -specific, niemory CDS T -cells to 
proliferate into armed, HY-specific effector cells. Control 
effectors, generated from female mice neither receiving priming 
nor PF, were identically cultured. 
Synthesis ofHY and LCMV-peptide 
With the assistance of Dr. Koeppe's biochemical research 
lab, the previously identified HY -peptide (amino acid sequence: 
KCSRNRQYL)(Markiewiecz, 1998)andLCMV-peptide(amino 
acid sequence: KA YVNFATM) (Kyburz.1993)were synthesized 
using the solid phase peptide synthesis (SPPS) technique 
(Merrifield, 1997). These synthetic peptides were designed to fit 
within the particular sequence motif of the mouse class I major 
histocompatibility complex (MHC I), D gene locus, b allele (H-
2.I)b) surface expressed molecule (Markiewiecz, 1998). The 
LCMV-peptide was employed as an H-2Db-binding control 
peptide such that it would bind into the MHC I but not become 
a recognizable target for the HY -specific effector cells. Each 
peptide was analyzed for purity by ultraviolet spectroscopy and 
High Performance Liquid Chromatography. 
RMA-S T -cell lymphoma line 
The female, immortal T-cell line, known as RMA-S 
(Ljunggren, 19S5), was employed as target cells to test for the 
cytotoxic killing ability of the previously in vitro generated ~y­
specific effector cells. The RMA -S cell is incapable of expressmg 
a stable MHC I due to a mutation in the Transporter associated 
with Antigen Presentation (TAP) gene locus (Kaer, 1992). 
However, if RMA-S cells are incubated with peptide known to 
bind within its MHC I (H-2Db), a stabile surfaced expressed 
MHC !:peptide complex is formed (Townsend, 1996). It is this 
critical complex that triggers the peptide-specific CDS T -cell to 
unleash its arsenal of cytotoxic chemicals upon the target cell. 
Thus, RMA-S cells were incubated with the previously 
synthesized HY and LCMV peptides for 16 hours prior to 51Cr 
labeling (see below) to create target cells. This technique is 
known as peptide loading. RMA -S cells without peptide loading 
are deficient in MHC class I. These become targets for Natural 
Killer cells and are therefore not an appropriate target population 
to serve as a control. 
Male Targets 
Male C57BUJ6 splenocytes were employed as alternative 
HY -antigenic target cells. 
Chromium-51 cytotoxic release assay 
The various RMA-S target cells were incubated with 100 
_Ciofradiolabeleddisodiumchromate(N~51Cr0). Thegamma 
energy emitting chromium-51 (51Cr) radionuclide is readily 
incorporated into the target cell cytosol via calcium ion channels 
(Co ligan, 1996). Spontaneous release and reuptake is relatively 
low due to irreversible binding of 51Cr with cytosolic protein 
(Co ligan, 1996). After one hour of incubation (at 3 7oo C and 5% 
CO,) the targets were washed three times. Effector cells were 
collected from their6 day cultures and cell recoveries determined. 
Within a 96-well V-bottom microtiter plate effector-to-target 
ratios of 50:1, 25:1 and 12: 1 were created in replicate with target 
cells constant at a quantity of 1 0"'. The assays were designed with 
nine to twelve effector:target combinations involving an 
intersecting grid of the three effector treatment groups and the 
three to four targets types in a total volume of200_l. Spontaneous 
51Cr release values were established with wells only containing 
target cells and complete media. The assay plate was centrifuged 
and incubated for six hours at 37oo C and5% CO,. This provided 
the proper physiological condition for CDS- cell-mediated, 
cytotoxic lysis of the 51Cr-labeled target cells (Rodrigues, 1992), 
and the subsequent release of their cytosolic51Cr into the 
surrounding media. After incubation the assay plate was 
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centrifuged and 150_1 of supernatant of each well was collected 
for gamma activity detection in a fully automated Packard 
Cobra® gamma counter. To establish a total, potential gamma 
count, 75_1 of each type of 51Cr labeled target cell stock was 
directly counted. Cytotoxic activity was correlated with gamma 
counts per minute (CPM) by the following equation: 
(Experimental CPM value-Spontaneous ReleaseCPM 
value) I (Total CPM value- Spontaneous Release 
CPM value) x 100 =%specific lysis 
Final cytotoxic activity, or percentage specific lysis, is a 
measure of the in vivo generated memory CDS T -cell contingent. 
Results 
Figure 1a provides data from the three treatment groups 
against HY -peptide loaded RMA-S target cells at a 50: 1 E:T ratio 
60 days post-priming in an HY-antigen system. The control 
effector cell group generated an expected low baseline specific 
lysis of S%. The untreated effector group (hatched bar) did not 
show any significant increase of specific lysis relative to the 
control group. The PF-treated effector cell group did show a 
significant (p=.042) increase of specifc lysis relative to the 
untreated group. Figure 1 b provides data from the three treatment 
effector cell groups against male splenocytes at a 50: 1 E:T ratio 
60 days post-priming in an HY-antigen system. The untreated 
control effector cell group (checkered bar) elicited an expected 
low basline specifc lysis of nearly 0%. The untreated effector 
cell group (hatched bar) did not show any significant increase of 
specific lysis relative to the control group. The PF-treated 
effector cell group (solid bar) did show a significant (p=.037) 
increase of specific lysis relative to the untreated group. 
Figure 2a provides data from the three treatment groups 
against the irrelevant control LCMV-peptide loaded RMA-S 
target cells at a 50:1 E:T ratio 90 days post-priming in an HY-
antigen system. All treatment groups elicited specific lysis 
values consistent with a non-specific target. Figure 2b provides 
data from the three treatment effector cell groups against HY-
peptide loaded RMA-S cells at a 50:1 E:T ratio 90 days post-
priming in an HY -antigen system. The untreated control effector 
cell group (checkered bar) elicited an expected low basline 
specifc lysis of 8%. The untreated effector cell group (hatched 
bar) did not show any significant increase of specific lysis 
relative to the control group. However, the PF-treated effector 
cell group (solid bar) did show a large significant (p=.019) 
increase of specific lysis relative to the untreated group. 
Figure 3a provides data from the three treatment groups 
against the irrelevant control LCMV -peptide loaded IU.IA-S 
target cells at a titrated E:T ratio from 50:1 to 12:1 60 days post-
priming in an THY 1.1-antigen system. All treatment gro~ps 
elicited specific lysis values consistent with a non-specific 
target. Figure 3b provides data from the three treatment e~ector 
cell groups against HY -peptide loaded RMA -S cells at a titrated 
E:T ratio from 50:1 to 12:1 60 days post-priming in an HY-
antigen system. The untreated control effector cell group 
(checkered bar) elicited an expected basline specifc lysis of S% 
and followed the titration trend. For the first time. the untreated 
effector cell group elicited a significant specific lysis relative to 
the control group along the titration curve. This data can be 
explained by more initial CD4 helper T-cell generated IL-2 
during priming due to the additional THYl.l antigen. The PF-
treated effector cell group demonstrated the largest significant 
increase (p<.005) of specific lysis. following the titration curve. 
relative to the untreated group. 
Most recently our lab designed and performed an experiment 
to determine if the observed enhanced memory cytotoxicity was 
a direct result of an increased memory CDS T -cell contingent and 
not exclusively a matter of help from CD4 memory helper T-
cells. Though several crucial steps were altered to bypass any 
potential CD4 T-cell help at the priming event, the general 
protocols of the previously described experiments were followed. 
Mice were primed with syngeneic female C57BU6J splenocytes 
loaded with the MHC !-specific LCMV-peptide to insure an 
exclusive CDS T -cell recognition of the MHC I:LCMV -peptide 
complexes. This procedure provided two experimentally relevant 
functions: LCMV peptide cannot stimulate a CD4 T -cell response 
and does not bind to the MHC II; and this CD4 bypass insured 
that any observed recall cytotoxicity was a direct result of a 
memory CDS T -cell contingent. 
107 Female splenocytes were loaded with 200_g ofLCMV-
peptide in a total volume of 1 rni of serum-free media and 
incubated for one hour at 37oo C and 5% C02" The serum-free 
media allowed the endogenous peptide of the splenocytes to 
briefly dissociate with their MHC I molecules. The 
__ microglobulin sub-unit of all MHC I is in a non-covalently 
bound/unbound state of equilibrium (Rock, 1991 ). Dissociation 
of the __ microglobulin sub-unit destabilizes the MHC I which 
leads to loss of its bound peptide. At this juncture, the 
thermodynamically advantaged (law of mass action) synthetic 
peptide usurps the original endogenous peptide position. Fetal 
calf serum typically employed to make cell culture media 
"complete" contains large quantities of ___ microglobulin sub-
units that have been shown to bind to mouse MHC I (Rock, 
1991 ). In terms of attempting to load splenocytes with exogenous 
peptide, this pushes the bound/unbound equilibrium to the 
unfavorable bound state. Thus, a serum-free medium is crucial 
to peptide loading. Each mouse was primed v.ith 107 LCMV-
peptide loaded cells and treatment-group mice received injections 
of PF at 1.5 mg per day per mouse on day -1 to day 4, relative 
to priming. On day 30, post -priming, spleens were harvested and 
cultured at the 5:1 E:T ratio with LC.MV -peptide loaded female 
splenocytes. In vitro generated LCMV -specific effector cells 
were mixed separately with 51Cr-labeled IU.1A-S cells loaded 
with LCMV -peptide or the irrelevant HY -peptide at an E:T ratio 
of25:1. 
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Figure 4 demonstrates that PF-treated effectors exhibited a 
greater LCMV -specific lysis than the non-treated effectors. This 
lends support to the claim that the previously observed enhanced 
CDS recall cytotoxicity is a direct result of an increased CDS T-
cell contingent. Though this particular experiment requires 
confirmation by repetition, these data offer a positive trend to the 
expectation of a PF-mediated memory CDS T-cell pool. 
In toto, these experiments designed with multiple control 
and experimental conditions provided statistically significant 
evidence to the proposed hypothesis that the presence of PF 
during priming enhances CDS T-cell immunological memory. 
Discussion 
The potency of the vaccine, as the premiere method of 
disease prevention and control, is founded on the ability to 
intentionally induce the generation oflong-lived, antigen-specific 
memory cells (Christensen, 1994). Though the vaccine is a 
fruitful discovery, it must be understood that it falls short of its 
potential. Within the vaccine-induced immune response the 
natural production of antigen-specific effector cells is without 
justification, for, ultimately, the stimulating agent is non-
pathogenic, only immunogenic. To advance the vaccine within 
the scope of its ideal, we must be able to shift the fulcrum of this 
balanced cell differentiation pathway to favor an exclusive and 
robust production within the memory cell contingent. PF has 
previously (Gupta, 1999) demonstrated the ability to diminish 
the CD4 T -cell primary response while enhancing CD4 memory. 
This work shows that PF enhances CDS T-cell recall activity. 
These experiments offer a tantalizing potential to expand the 
reach of our preventative intentions. 
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Faculty Comments: 
Mr.Goodspeed'sfacultymentor,Dr.JeannineM.Durdik, 
made the following comments about his project: 
This letter is to explain the value and pertinence of the 
work of Eric Goodspeed, an undergraduate researcher 
in my lab, who has made a very important and 
independent contribution. 
For successful protection against various infections, 
the development of an adoptive immune response is 
necessary. When the same infection is encountered 
again by the individual, the immune response 
specifically directed against target molecules of the 
infectious organism is significantly different from 
that seen during the first encounter in being much 
larger. This ability of the immune system to 
"remember" past history and respond better to 
reinfection is called immune memory. 
However, in response to an infection, cells of the 
immune systemmustnot only generate this quiescent 
state called immune memory, but must also mount a 
response that is immediately effective and useful in 
combating the ongoing infection. This pathway of 
immune cell differentiation must thus lead to the 
development of effector cells. Since effector cells are 
to be used immediately, a major difference between 
memory and effector cells is that memory cells must 
be capable of undergoing proliferation upon antigen 
re-exposure, while effector cells must be capable of 
immediate function without proliferating. The 
immune system, in response to a natural infection, 
must therefore strike a balance between the generation 
of memory and effector cells. 
However, the requirements are significantly different 
during vaccination. Vaccination, as commonly 
understood, is a mock infection, in that it exposes the 
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body to the molecular targets of a given infectious 
agent without actually causing disease. Thus, there is 
no immediate need for effector immune responses to 
vaccination. 
The pathways that strike a balance between effector 
and memory commitment are mutually exclusive, so 
that stimulating the immune system too hard may 
lead to the generation of short-lived effector immune 
cells to the detriment of the generation of longlived 
memory immune cells. A dilemma is thus apparent; 
overstimulating the immune system by a vaccine may 
be detrimental to the generation of immune memory 
against it, but understimulation may also result in 
poor generation of both effector and memory 
responses. The solution to this difficulty is the 
identification and use of immune response mod)fiers 
that affect the biochemical pathways governing 
effector versus memory generation differentially. Such 
modulators should suppress effector generation and 
skew tne balance in favor of memory generation. 
What Eric has done is describe such an 
immunomodulatory intervention and how it relates 
to memory generation for one branch of the immune 
response, killer T cells. He has discovered that by 
administering the drug pentoxifylline during 
immunization that he can demonstrate the persistence 
of immune memory 100 days later. Without this 
treatment, there is practically no detectable T cell 
killing. This finding will have a significant impact on 
the field of immunology. 
Dr. Dwight E. F. Talhurt,ProfessorandVice-Chairofthe 
Department of Biological Sciences said of Mr. Goodspeed's 
work: 
I feel that Eric is both and outstanding individual as 
well as a student. I have known him for about 3 years 
while he has been a student major in the Department 
of Biological Sciences. Also, he was a student in my 
senior I graduate level course in Microbial Physiology 
where he demonstrated clearly his ability to assimilate 
and gain understanding of a large body of technical 
informationconcerningthe biochemistry and genetics 
which underlie microbial growth. In this class he was 
in the top 5% of about 60 advanced students. Overall, 
hisGPAisabout3.6.Inadditiontohisstrongclassroom 
and laboratory abilities, Mr. Goodspeed has been 
active in various honorary and community service 
endeavors. 
Mr. Goodspeed's work, which he seeks to publish in 
Inquiry, is an outgrowth of work which he began with 
a "SILO Undergraduate Research Fellowship" under 
the very able direction of his mentor and research 
advisor, Dr. Jeannine Durdik. The work is entitled 
"PentoxifyllinemodulationofthecytotoxicCD8 T -Cell 
differentiation pathway to enhance the memory cell 
contingent"-which means that he an his advisor 
have possibly discovered a way to enhance immune 
responses to disease causing agents. If so, the 
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application of this agent (pentoxifylline), or some 
derivative of it, into a vaccine might be an effective 
approach to eliciting stronger immune responses by 
the individuals who receive the \'accines. 
Dr. Douglas Rhoads, Associate Professor and Vice-chair 
of the Department of Biological Sciences, had this to say about 
Mr. Goodspeed: 
I have been asked to provide a letter of support 
regarding the submission by Mr. Eric Goodspeed of 
an abstract and project for a research award and for 
publication in the new U of A undergraduate journal, 
Inquiry. I can think of no student that is more 
appropriate or more deserving of such an award. I 
had Eric in Cell Biology Lecture and Lab. Eric clearly 
distinguished himself in this course as one of the 
brightest and most dedicated and attentive students 
in the class of 90 students. This is an intensive course 
incellmetabolismandstructure. Theexamsallrequire 
lengthy, hand written answers to questions based on 
the readings and lectures. Eric sat near the front, 
attendedallbutonelectureandaskedsomeofthebest 
questions. The only period he missed he came to me 
and apologized for missing. He scored extremely well 
onalltheexamsandhadoneofthehighestcumulative 
scores in the class. For that reason I kept in contact 
with Eric and advised him about getting involved in 
a research project for his senior thesis requirement. 
Unfortunately, he selected to work in Dr. Jeannine 
Durdik'slab. That is unfortunate forme because I was 
hoping he would choose my lab. It is fortunate for him 
and for Dr. Durdik that he chose her lab. I am well 
aware of Dr. Durdik's research program as I have 
been on several thesis committees for her graduate 
and Undergraduate students. Dr. Durdik molds 
thinkers and researchers trained in immunology and 
molecular biology. The students receive a well 
rounded education and training that is competitive 
with the best University settings: I think Eric has been 
very successful in his undergraduate project. I have 
witnessed him on weekdays, weekends and evenings 
working in the lab. He enjoys the work and appears 
quite dedicated to his science. I will add that his 
personality and attitude make him pleasant to 
converse with and open to suggestion and discussion. 
I have read the abstract to his proposal and am excited 
about the possibility that Dr. Durdik and Eric will be 
extending the work on pentoxifylline to CDS+ cells. 
As this effort has the potential to develop new 
patent-able drugs for human health I find it well 
worth pursuing. I give Eric Goodspeed my highest 
rating, I think he is in the top 1-5% of all our students 
in Biological Sciences (class of 600). I highly 
recommend that you publish his findings and award 
him for this effort. 
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Figure 1. PF-mediated enhancement of CDS T -cell memory in vivo 60 days post-priming. Female C57BL/ 6J mice primed with 1()1 
C57BL/6J splenocytes were treated either with PBS or l.SmgPF per mouse per day from day-one to day-four of priming. Splenocytes 
at day-sixty post-priming from unprimed (checkered bar), primed+PBS-treated (hatched bar) or primed+PF-treated (solid bar) were 
stimulatedinvitroforsixdayswithmalesplenocytesandusedaseffectorcellsata50:1effector:targetratiotolyse(a)51Cr-labeledRMA-
S target cells incubated with HY-peptide or (b) 51Cr-labeled male splenocyte targets in a six-hour cytotoxic assay to determine 
percentage of cytotoxicity. 
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Figure 2. PF-mediated enhancement of CDS T-cell memory in vivo 90 days post-priming. Female C57BL/ 6J mice primed with 107 
male C57BL/ 6J splenocytes were treated either with PBS or 1.5 mg PF per mouse per day from day -1 to day 4 of priming. Splenocytes 
at day 60 post-priming from unprimed (checkered bar), primed+PB5-treated (hatched bar) or primed+PF-treated (solid bar) were 
stimulated in vitro for 6 days with male splenocytes and used as effector cells at a 50:1 effector:target ratio to lyse (a) 51Cr-labeled 1Uv1A-
S target cells loaded with the irrelevant LCMV -peptide or (b) 51Cr-labeled HY -peptide loaded IUvfA-5 targets in a 6-hour cytotoxic assay 
to determine percentage of cytotoxicity. 
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Figure 3. PF-mediated enhancement of CDS T -cell in vivo 60 days post-priming. Female C57BL/6J mice primed with 10" male THYl.l splenocytes 
were treated either with PBS of 1.5mg PF per mouse per day from day-one to day-four of priming. Splenocytes at day 60 post-priming from unprimed 
(square), primed+ PBS-treated (triangle) of primed+PF-treated (diamond) were stimulated in vitro for six days with male splenocytes and used as effector 
cells at effector:target rations of 50:1, 25:1 (and 12:1 in B) to lyse (A) 51Cr-baleled RMA-5 target cells loaded with the irrelevant LCMV -peptide of (B) 51Cr-
labeled RMA-5 targets loaded with the HY-peptide in a six-hour cytotoxic assay to determine percentage of cytotoxicity. 
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Figure 4. Generation of an MHC class I restricted CDS T-cell response by priming with LCMV-peptide loaded cells. Female C57BL/ 
6J mice were primed with LCMV-peptide loaded syngeneic female splenocytes. Restimulated LCMV -specific effectors were developed 30 days post-
priming and mixed with 51Cr-labeled, LCMV-peptide loaded RMA-5 cells at an effector: target ratio of 25:1 (2.5x10S:lx1Ql ). LCMV-primed, PF-
treated mice-generated effectors (solid bar) show a greater cytotoxic activity against the LCMV-peptide loaded RMA-5 target cell than the untreated 
LCMV-specific effectors (hatched bar). 
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